Lyra Therapeutics Inc expected to post a loss of $6.02 a share - Earnings Preview

Lyra Therapeutics

08/08/2025 14:26

Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

The Watertown Massachusetts-based  company is expected to report a 71.4% decrease in revenue to $171.25 thousand from $598 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lyra Therapeutics Inc is for a loss of $6.02 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 70% above its last closing price of $6.89

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-7.50
-6.83
-6.00
Beat
12.2
Dec. 31 2025
-6.26
-6.00
-8.00
Missed
-33.3
Sep. 30 2024
-10.46
-11.40
-9.00
Beat
21.1​
Jun. 30 2024
-16.42
-16.40
-37.00
Missed
-125.6
​​Mar. 31 2024
-13.32
-13.10
-17.50
Missed
-33.6
Dec. 31 2023
-15.75
-11.00
Beat
30.2​
Sep. 30 2023
-15.51
-15.90
-13.50
Beat
15.1
Jun. 30 2023
-20.04
-21.17
-16.00
Beat
24.4

This summary was machine generated August 8 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)